Home › Funds › KBC Group NV › GILD

KBC Group NV position in GILD

GILEAD SCIENCES INC · Health Care

KBC Group NV reported holding 1,419,452 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$211.6M, representing 0.44% of its reported portfolio and ranking #36 among its reported holdings. KBC Group NV has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)1.42M sh
Reported value held$211.57M
Portfolio Weight0.44%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How KBC Group NV's GILD position evolved

KBC Group NV first disclosed a stake in GILD in Q3 2023 at 1,236,755 shares (US$92.7M). The position peaked in Q4 2025 at 3,244,626 shares, worth US$398.2M. Across 13 filings, KBC Group NV increased the stake 6 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,419,452 shares valued at US$211.6M — a reduction of -224,583 shares quarter over quarter.. Notable position changes include a 122% increase in Q1 2024 (shares fell 6% over the following quarter), a 37% trim in Q3 2024 (shares rose 11% over the following quarter), a 39% trim in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.24M $92.68M New
Q4 2023 1.42M $115.16M Add
Q1 2024 3.16M $231.41M Add
Q2 2024 3.63M $248.86M Add
Q3 2024 2.28M $191.37M Reduce
Q4 2024 2.06M $190.43M Reduce
Q1 2025 1.85M $206.74M Reduce
Q2 2025 2.34M $259.63M Add
Q3 2025 2.96M $328.67M Add
Q4 2025 3.24M $398.25M Add
Q1 2026 2.68M $373.46M Reduce
Q2 2026 1.64M $207.71M Reduce
Q3 2026 1.42M $211.57M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 34 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.68B), Invesco Ltd (US$5.76B), Capital World Investors (US$5.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has KBC Group NV held GILD?

KBC Group NV has disclosed GILD holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is KBC Group NV's current position in GILD?

As of Q3 2026, KBC Group NV holds 1.42M shares of GILD (GILEAD SCIENCES INC), valued at $211.57M, representing 0.44% of its reported portfolio and ranking #36.

Has KBC Group NV been buying or selling GILD?

In the latest 13F filing (Q3 2026), KBC Group NV reduced its position in GILD. The position peaked in Q4 2025 at 3.24M shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Invesco Ltd, Capital World Investors, among 34 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.